Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US38341P1021
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Mo., 04.05.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - May 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"), of the important June 1, 2026 lead plaintiff deadline.SO WHAT: If you purchased Gossamer secur...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
So., 03.05.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. I...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Gossamer Bio
US38341P1021

NEW YORK, April 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and Feb...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Gossamer Bio
US38341P1021

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 30, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged violations o...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Gossamer Bio
US38341P1021

Time-Sensitive: Allegations Focus on PROSERA Patient Selection RepresentationsNEW YORK, April 30, 2026 /PRNewswire/ -- SueWallSt alerts investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a pending securities class action seeks to recover damages for shareholders who purchased securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 30, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. I...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Gossamer Bio
US38341P1021

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatme...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 29.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Gossamer Bio
US38341P1021

San Francisco, California--(Newsfile Corp. - April 29, 2026) - A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.The lawsuit follows Gossamer's bombshell announ...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 29, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS)....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Gossamer Bio
US38341P1021

The Red Flags: What Insiders Allegedly Knew Before Shareholders DidNEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS). Y...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. I...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Gossamer Bio
US38341P1021

BENSALEM, Pa., April 28, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTAC...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to c...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 27, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 27.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 27, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 27.04.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - April 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
So., 26.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 24, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) have opportunity to lead the securities fraud class action lawsuit....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Gossamer Bio
US38341P1021

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026. Gossamer describes itself as a “clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 23.04.2026       Gossamer Bio
US38341P1021

Notice to Pension Funds, Asset Managers, and FiduciariesNEW YORK, April 23, 2026 /PRNewswire/ -- Institutional investors holding positions in Gossamer Bio, Inc. (NASDAQ: GOSS) during the period between June 16, 2025 and February 20, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutiona...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Gossamer Bio
US38341P1021

Promise vs. Reality: The Gossamer Bio PROSERA Performance GapNEW YORK, April 22, 2026 /PRNewswire/ -- "We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 22.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 21, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Gossamer Bio
US38341P1021

"We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session. Levi & Korsinsky, LLP notifies investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a securities cla...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 21.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to c...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 20, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Sa., 18.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Gossamer Bio
US38341P1021

SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail ar...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 16.04.2026       Gossamer Bio
US38341P1021

Deadline Alert: Understanding Lead Plaintiff Selection Under the PSLRANEW YORK, April 16, 2026 /PRNewswire/ -- IMPORTANT DATE: June 1, 2026. Investors who purchased Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your clai...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 15, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS)....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Gossamer Bio
US38341P1021

Notice to Pension Funds, Asset Managers, and FiduciariesNEW YORK, April 15, 2026 /PRNewswire/ -- Institutional investors holding positions in Gossamer Bio, Inc. (NASDAQ: GOSS) during the period between June 16, 2025 and February 20, 2026 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutiona...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Gossamer Bio
US38341P1021

BENSALEM, Pa., April 14, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTAC...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Mo., 13.04.2026       Gossamer Bio
US38341P1021

PHILADELPHIA, April 13, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the "Class Period")....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
So., 12.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Sa., 11.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 10, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) have opportunity to lead the securities fraud class action lawsuit....
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Fr., 10.04.2026       Gossamer Bio
US38341P1021

Lead Plaintiff Deadline June 1, 2026NEW YORK, April 10, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS) securities between June 16, 2025 and February 2...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Zur Nachricht
Gossamer Bio
Charts & Research Termsheets Terminal
Permalink